Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Show all queries
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00153101
Registration number
NCT00153101
Ethics application status
Date submitted
9/09/2005
Date registered
12/09/2005
Date last updated
20/05/2014
Titles & IDs
Public title
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
Query!
Scientific title
ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.
Query!
Secondary ID [1]
0
0
502.373
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cardiovascular Diseases
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
Query!
Assessment method [1]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
Query!
Timepoint [1]
0
0
56 months
Query!
Primary outcome [2]
0
0
ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients
Query!
Assessment method [2]
0
0
ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR \<15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) =300 mg/g Crea at baseline.
These renal outcomes were not adjudicated (apart from death).
Query!
Timepoint [2]
0
0
56 months
Query!
Primary outcome [3]
0
0
TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
Query!
Assessment method [3]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
Query!
Timepoint [3]
0
0
56 months
Query!
Secondary outcome [1]
0
0
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
Query!
Assessment method [1]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, non-fatal myocardial infarction or non-fatal stroke
Query!
Timepoint [1]
0
0
56 months
Query!
Secondary outcome [2]
0
0
ONTARGET. Cardiovascular Death
Query!
Assessment method [2]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint cardiovascular death.
Query!
Timepoint [2]
0
0
56 months
Query!
Secondary outcome [3]
0
0
ONTARGET. Non-fatal Myocardial Infarction
Query!
Assessment method [3]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint non-fatal myocardial infarction.
Query!
Timepoint [3]
0
0
56 months
Query!
Secondary outcome [4]
0
0
ONTARGET. Non-fatal Stroke
Query!
Assessment method [4]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the endpoint non-fatal stroke.
Query!
Timepoint [4]
0
0
56 months
Query!
Secondary outcome [5]
0
0
ONTARGET. Hospitalization for Congestive Heart Failure
Query!
Assessment method [5]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint hospitalization for congestive heart failure.
Query!
Timepoint [5]
0
0
56 months
Query!
Secondary outcome [6]
0
0
ONTARGET. Doubling of Serum Creatinine in Diabetic Nephropathy Patients
Query!
Assessment method [6]
0
0
Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) =300 mg/g Crea at baseline.
Query!
Timepoint [6]
0
0
56 months
Query!
Secondary outcome [7]
0
0
ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients
Query!
Assessment method [7]
0
0
ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR \<15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) =300 mg/g Crea at baseline.
Query!
Timepoint [7]
0
0
56 months
Query!
Secondary outcome [8]
0
0
ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients
Query!
Assessment method [8]
0
0
Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) =300 mg/g Crea at baseline.
Query!
Timepoint [8]
0
0
56 months
Query!
Secondary outcome [9]
0
0
ONTARGET. Doubling of Serum Creatinine
Query!
Assessment method [9]
0
0
ONTARGET. Nephropathy subcategory: doubling of serum creatinine
Query!
Timepoint [9]
0
0
56 months
Query!
Secondary outcome [10]
0
0
ONTARGET. Progression to ESRD
Query!
Assessment method [10]
0
0
ONTARGET. Nephropathy subcategory: Progression to ESRD. Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR \<15 mL/min/1.73 m².
Query!
Timepoint [10]
0
0
56 months
Query!
Secondary outcome [11]
0
0
ONTARGET. New Microalbuminuria
Query!
Assessment method [11]
0
0
ONTARGET. Nephropathy subcategory: New microalbuminuria. New microalbuminuria is defined as Urinary Albumin Creatinine Ratio =30 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio \<30 mg/g Crea at baseline.
Query!
Timepoint [11]
0
0
56 months
Query!
Secondary outcome [12]
0
0
ONTARGET. New Macroalbuminuria
Query!
Assessment method [12]
0
0
ONTARGET. Nephropathy subcategory: New macroalbuminuria. New macroalbuminuria is defined as Urinary Albumin Creatinine Ratio =300 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio \<300 mg/g Crea at baseline.
Query!
Timepoint [12]
0
0
56 months
Query!
Secondary outcome [13]
0
0
ONTARGET. Combined Endpoint of Doubling of Serum Creatinine, Progression to ESRD, New Microalbuminuria, or New Macroalbuminuria
Query!
Assessment method [13]
0
0
ONTARGET. Nephropathy subcategory: Combined endpoint of doubling of serum creatinine, progression to ESRD, new microalbuminuria, or new macroalbuminuria
Query!
Timepoint [13]
0
0
56 months
Query!
Secondary outcome [14]
0
0
ONTARGET. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria
Query!
Assessment method [14]
0
0
ONTARGET. Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria. Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR \<30 mg/g Crea in patients with a UACR =30 mg/g Crea at baseline.
Query!
Timepoint [14]
0
0
56 months
Query!
Secondary outcome [15]
0
0
ONTARGET. Newly Diagnosed Congestive Heart Failure
Query!
Assessment method [15]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint Newly diagnosed Congestive Heart failure.
Query!
Timepoint [15]
0
0
56 months
Query!
Secondary outcome [16]
0
0
ONTARGET. Cardiovascular Revascularization Procedure
Query!
Assessment method [16]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Query!
Timepoint [16]
0
0
56 months
Query!
Secondary outcome [17]
0
0
ONTARGET. Newly Diagnosed Diabetes
Query!
Assessment method [17]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint Newly diagnosed Diabetes. Only calculated for those patients without diabetes at baseline.
Query!
Timepoint [17]
0
0
56 months
Query!
Secondary outcome [18]
0
0
ONTARGET. Cognitive Decline
Query!
Assessment method [18]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the endpoint cognitive decline i.e. Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial. A decrease in MMSE from baseline represents a cognitive decline. This outcome measure is only available for those patients who had MMSE at baseline.
Query!
Timepoint [18]
0
0
56 months
Query!
Secondary outcome [19]
0
0
ONTARGET. New Onset of Atrial Fibrillation
Query!
Assessment method [19]
0
0
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of endpoint new onset of atrial fibrillation.
Query!
Timepoint [19]
0
0
56 months
Query!
Secondary outcome [20]
0
0
TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
Query!
Assessment method [20]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
Query!
Timepoint [20]
0
0
56 months
Query!
Secondary outcome [21]
0
0
TRANSCEND. Cardiovascular Death
Query!
Assessment method [21]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint cardiovascular death.
Query!
Timepoint [21]
0
0
56 months
Query!
Secondary outcome [22]
0
0
TRANSCEND. Non-fatal Myocardial Infarction
Query!
Assessment method [22]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint non-fatal myocardial infarction.
Query!
Timepoint [22]
0
0
56 months
Query!
Secondary outcome [23]
0
0
TRANSCEND. Non-fatal Stroke
Query!
Assessment method [23]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Query!
Timepoint [23]
0
0
56 months
Query!
Secondary outcome [24]
0
0
TRANSCEND. Hospitalization for Congestive Heart Failure
Query!
Assessment method [24]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Query!
Timepoint [24]
0
0
56 months
Query!
Secondary outcome [25]
0
0
TRANSCEND. Doubling of Serum Creatinine
Query!
Assessment method [25]
0
0
TRANSCEND. Nephropathy subcategory: doubling of serum creatinine
Query!
Timepoint [25]
0
0
56 months
Query!
Secondary outcome [26]
0
0
TRANSCEND. Progression to ESRD
Query!
Assessment method [26]
0
0
TRANSCEND. Nephropathy subcategory: Progression to ESRD. Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR \<15 mL/min/1.73m²
Query!
Timepoint [26]
0
0
56 months
Query!
Secondary outcome [27]
0
0
TRANSCEND. New Microalbuminuria
Query!
Assessment method [27]
0
0
TRANSCEND. Nephropathy subcategory: New microalbuminuria. New microalbuminuria is defined as UACR =30 mg/g creatinine \[Crea\] in patients with a UACR \<30 mg/g Crea at baseline
Query!
Timepoint [27]
0
0
56 months
Query!
Secondary outcome [28]
0
0
TRANSCEND. New Macroalbuminuria
Query!
Assessment method [28]
0
0
TRANSCEND. Nephropathy subcategory: New macroalbuminuria. New macroalbuminuria is defined as UACR =300 mg/g creatinine \[Crea\] in patients with a UACR \<300 mg/g Crea at baseline
Query!
Timepoint [28]
0
0
56 months
Query!
Secondary outcome [29]
0
0
TRANSCEND. Combined Endpoint of Doubling Serum Creatinine, Progression to ESRD, New Microalbuminuria or New Macroalbuminuria
Query!
Assessment method [29]
0
0
TRANSCEND. Nephropathy subcategory: Combined endpoint of doubling serum creatinine, progression to ESRD, new microalbuminuria or new macroalbuminuria
Query!
Timepoint [29]
0
0
56 months
Query!
Secondary outcome [30]
0
0
TRANSCEND. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria
Query!
Assessment method [30]
0
0
TRANSCEND. Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria. Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR \<30 mg/g Crea in patients with a UACR =30 mg/g Crea at baseline.
Query!
Timepoint [30]
0
0
56 months
Query!
Secondary outcome [31]
0
0
TRANSCEND. New Onset of Atrial Fibrillation
Query!
Assessment method [31]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Query!
Timepoint [31]
0
0
56 months
Query!
Secondary outcome [32]
0
0
TRANSCEND. Cognitive Decline
Query!
Assessment method [32]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the endpoint cognitive decline i.e. Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial. A decrease in MMSE from baseline represents a cognitive decline. This outcome measure is only available for those patients who had MMSE at baseline.
Query!
Timepoint [32]
0
0
56 months
Query!
Secondary outcome [33]
0
0
TRANSCEND. Newly Diagnosed Diabetes
Query!
Assessment method [33]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint Newly diagnosed Diabetes. Only calculated for those patients without diabetes at baseline.
Query!
Timepoint [33]
0
0
56 months
Query!
Secondary outcome [34]
0
0
TRANSCEND. Cardiovascular Revascularization Procedure
Query!
Assessment method [34]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Query!
Timepoint [34]
0
0
56 months
Query!
Secondary outcome [35]
0
0
TRANSCEND. Newly Diagnosed Congestive Heart Failure
Query!
Assessment method [35]
0
0
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Query!
Timepoint [35]
0
0
56 months
Query!
Eligibility
Key inclusion criteria
Coronary Artery Disease: Previous Myocardial infarction(> 2 days prior to informed consent), or stable or previous unstable angina (> 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (> 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Grafting without angina (if surgery performed > 4 years prior to informed consent) or with recurrent angina after surgery.
Other High Risk:
1. Peripheral Arterial Disease: Previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure ratio < 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing
2. Previous stroke
3. Transient ischemic Attack > 7 days and < 1 year prior to informed consent
4. Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left ventricular hypertrophy, micro or macro albuminuria), or any evidence of previous cardiac or vascular disease.
No definite and specific indication or contraindication for any of the study treatments. Written informed consent.
Query!
Minimum age
55
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
A. Medication use:
1. Inability to discontinue Angiotension Converting Enzyme (ACE) inhibitors or Angiotension 2 receptor antagonists (AIIAs).
2. Patients with known hypersensitivity or intolerance to Angiotension 2 receptor antagonists (AIIAs) or Angiotension Converting Enzyme (ACE)inhibitors.
NOTE: Patients with known intolerance to Angiotension Converting Enzyme inhibitor intolerance ( ACE-I) can be enrolled in the TRANSCEND study.
B. Cardiovascular disease:
1. Symptomatic congestive heart failure.
2. Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve).
3. Constrictive pericarditis.
4. Complex congenital heart disease.
5. Syncopal episodes of unknown etiology < 3 months before informed consent.
6. Planned cardiac surgery or angioplasty within three months.
7. Uncontrolled hypertension on treatment (i.e.Blood pressure ( BP) > 160/100).
8. Heart transplant recipient.
9. Strokes due to subarachnoid hemorrhage
C. Other conditions:
1. Significant renal disease defined as:
1. Renal artery stenosis;
2. Creatinine clearance < 0.6 ml/min or serum creatinine > 265 umol/L (> 3.0 mg/dL);
3. Hyperkalemia: potassium > 5.5 mmol/L.
4. Proteinuria* (for TRANSCEND only).
2. Hepatic dysfunction as defined by the following laboratory parameters: Serum Glutamate Pyruvate Transaminase( SGPT) Alaninaminotransferase (ALT) or Serum Glutamic Oxaloacetic Transaminase (SGOT) Aspartate aminotransferase (AST) > than 4 times upper limit of normal or additional criteria for hepatic impairment the upper limit of normal range, total Bilirubin > 20 umol/L, biliary obstructive disorders.
3. Uncorrected volume depletion or sodium depletion.
4. Primary aldosteronism.
5. Hereditary fructose intolerance.
6. Any other major non-cardiac illness expected to reduce life expectancy or interfere with study participation.
7. Patient is simultaneously taking another experimental drug.
8. Patient with significant disability that precludes regular attendance at clinic for follow-up.
9. Patient has sufficient disability or other incapacity that precludes regular attendance at clinic for follow-up.
10. Unable or unwilling to provide written informed consent.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2001
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
31546
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
502.373.0534 The Canberra Hospital - Woden
Query!
Recruitment hospital [2]
0
0
502.373.0536 Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [3]
0
0
502.373.0544 Coffs Harbour Cardiovascular Clinic - Coffs Harbour
Query!
Recruitment hospital [4]
0
0
502.373.0538 Concord Repatriation General Hospital - Concord
Query!
Recruitment hospital [5]
0
0
502.373.0539 Central Coast Neuroscience Research - Gosford
Query!
Recruitment hospital [6]
0
0
502.373.0556 Gosford Hospital - Gosford
Query!
Recruitment hospital [7]
0
0
502.373.0542 St. George Hospital - Kogarah
Query!
Recruitment hospital [8]
0
0
502.373.0552 St George Private Hospital - Kogarah
Query!
Recruitment hospital [9]
0
0
502.373.0559 St George Hospital - Dept of Clinical Pharmacology - Kogarah
Query!
Recruitment hospital [10]
0
0
502.373.0528 John Hunter Hospital - Newcastle
Query!
Recruitment hospital [11]
0
0
502.373.0535 The Prince of Wales Hospital - Randwick
Query!
Recruitment hospital [12]
0
0
502.373.0533 Royal North Shore Hospital - St Leonards
Query!
Recruitment hospital [13]
0
0
502.373.0549 Illawarra Regional Hospital - Wollongong
Query!
Recruitment hospital [14]
0
0
502.373.0523 The Prince Charles Hospital - Chermside
Query!
Recruitment hospital [15]
0
0
502.373.0524 Royal Brisbane Hospital - Herston
Query!
Recruitment hospital [16]
0
0
502.373.0526 Peninsula Clinical Research Centre - Kippa-Ring
Query!
Recruitment hospital [17]
0
0
502.373.0540 Gold Coast Hospital - Southport
Query!
Recruitment hospital [18]
0
0
502.373.0521 Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [19]
0
0
502.373.0546 Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [20]
0
0
502.373.0550 Repatriation General Hospital - Daw Park
Query!
Recruitment hospital [21]
0
0
502.373.0551 Port Lincoln "The Investigator" Clinic - Port Lincoln
Query!
Recruitment hospital [22]
0
0
502.373.0529 Launceston General Hospital - Launceston
Query!
Recruitment hospital [23]
0
0
502.373.0531 Box Hill Hospital - Box Hill
Query!
Recruitment hospital [24]
0
0
502.373.0548 The Northern Hospital - Epping
Query!
Recruitment hospital [25]
0
0
502.373.0522 The Geelong Hospital - Geelong
Query!
Recruitment hospital [26]
0
0
502.373.0520 Royal Melbourne Hospital - Parkville
Query!
Recruitment hospital [27]
0
0
502.373.0525 The Alfred Hospital - Prahran
Query!
Recruitment hospital [28]
0
0
502.373.0532 Baker Medical Research Centre - Prahran
Query!
Recruitment hospital [29]
0
0
502.373.0557 Maroondah Hospital - Ringwood East
Query!
Recruitment hospital [30]
0
0
502.373.0537 Austin & Repatriation Medical Centre - West Heidelberg
Query!
Recruitment hospital [31]
0
0
502.373.0547 Fremantle Hospital - Fremantle
Query!
Recruitment hospital [32]
0
0
502.373.0530 Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment hospital [33]
0
0
502.373.0545 Royal Perth Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
- Woden
Query!
Recruitment postcode(s) [2]
0
0
- Camperdown
Query!
Recruitment postcode(s) [3]
0
0
- Coffs Harbour
Query!
Recruitment postcode(s) [4]
0
0
- Concord
Query!
Recruitment postcode(s) [5]
0
0
- Gosford
Query!
Recruitment postcode(s) [6]
0
0
- Kogarah
Query!
Recruitment postcode(s) [7]
0
0
- Newcastle
Query!
Recruitment postcode(s) [8]
0
0
- Randwick
Query!
Recruitment postcode(s) [9]
0
0
- St Leonards
Query!
Recruitment postcode(s) [10]
0
0
- Wollongong
Query!
Recruitment postcode(s) [11]
0
0
- Chermside
Query!
Recruitment postcode(s) [12]
0
0
- Herston
Query!
Recruitment postcode(s) [13]
0
0
- Kippa-Ring
Query!
Recruitment postcode(s) [14]
0
0
- Southport
Query!
Recruitment postcode(s) [15]
0
0
- Woolloongabba
Query!
Recruitment postcode(s) [16]
0
0
- Bedford Park
Query!
Recruitment postcode(s) [17]
0
0
- Daw Park
Query!
Recruitment postcode(s) [18]
0
0
- Port Lincoln
Query!
Recruitment postcode(s) [19]
0
0
- Launceston
Query!
Recruitment postcode(s) [20]
0
0
- Box Hill
Query!
Recruitment postcode(s) [21]
0
0
- Epping
Query!
Recruitment postcode(s) [22]
0
0
- Geelong
Query!
Recruitment postcode(s) [23]
0
0
- Parkville
Query!
Recruitment postcode(s) [24]
0
0
- Prahran
Query!
Recruitment postcode(s) [25]
0
0
- Ringwood East
Query!
Recruitment postcode(s) [26]
0
0
- West Heidelberg
Query!
Recruitment postcode(s) [27]
0
0
- Fremantle
Query!
Recruitment postcode(s) [28]
0
0
- Nedlands
Query!
Recruitment postcode(s) [29]
0
0
- Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
District of Columbia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Idaho
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Illinois
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Iowa
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Mississippi
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Missouri
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nebraska
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Nevada
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New Jersey
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New York
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
North Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
North Dakota
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Ohio
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Oklahoma
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Oregon
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Pennsylvania
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
South Carolina
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Texas
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Virginia
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Washington
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Wisconsin
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Capital Federal
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Corones Suárez
Query!
Country [36]
0
0
Argentina
Query!
State/province [36]
0
0
Córdoba
Query!
Country [37]
0
0
Argentina
Query!
State/province [37]
0
0
La Plata
Query!
Country [38]
0
0
Argentina
Query!
State/province [38]
0
0
Mar del Plata
Query!
Country [39]
0
0
Argentina
Query!
State/province [39]
0
0
Mendoza
Query!
Country [40]
0
0
Argentina
Query!
State/province [40]
0
0
Rosario
Query!
Country [41]
0
0
Argentina
Query!
State/province [41]
0
0
Salta
Query!
Country [42]
0
0
Argentina
Query!
State/province [42]
0
0
Santa Fe
Query!
Country [43]
0
0
Argentina
Query!
State/province [43]
0
0
Tucumán
Query!
Country [44]
0
0
Argentina
Query!
State/province [44]
0
0
Zárate
Query!
Country [45]
0
0
Austria
Query!
State/province [45]
0
0
Graz
Query!
Country [46]
0
0
Austria
Query!
State/province [46]
0
0
Wels
Query!
Country [47]
0
0
Austria
Query!
State/province [47]
0
0
Wien
Query!
Country [48]
0
0
Belgium
Query!
State/province [48]
0
0
Aalst
Query!
Country [49]
0
0
Belgium
Query!
State/province [49]
0
0
Anderlecht
Query!
Country [50]
0
0
Belgium
Query!
State/province [50]
0
0
Antwerpen
Query!
Country [51]
0
0
Belgium
Query!
State/province [51]
0
0
Bornem
Query!
Country [52]
0
0
Belgium
Query!
State/province [52]
0
0
Brasschaat
Query!
Country [53]
0
0
Belgium
Query!
State/province [53]
0
0
Brugge
Query!
Country [54]
0
0
Belgium
Query!
State/province [54]
0
0
Charleroi
Query!
Country [55]
0
0
Belgium
Query!
State/province [55]
0
0
Genk
Query!
Country [56]
0
0
Belgium
Query!
State/province [56]
0
0
Godinne
Query!
Country [57]
0
0
Belgium
Query!
State/province [57]
0
0
Haine-Saint-Paul
Query!
Country [58]
0
0
Belgium
Query!
State/province [58]
0
0
Hasselt
Query!
Country [59]
0
0
Belgium
Query!
State/province [59]
0
0
Leuven
Query!
Country [60]
0
0
Belgium
Query!
State/province [60]
0
0
Mechelen
Query!
Country [61]
0
0
Belgium
Query!
State/province [61]
0
0
Mol
Query!
Country [62]
0
0
Belgium
Query!
State/province [62]
0
0
Roeselare
Query!
Country [63]
0
0
Belgium
Query!
State/province [63]
0
0
Seraing
Query!
Country [64]
0
0
Belgium
Query!
State/province [64]
0
0
Turnhout
Query!
Country [65]
0
0
Belgium
Query!
State/province [65]
0
0
Woluwé-Saint-Lambert
Query!
Country [66]
0
0
Brazil
Query!
State/province [66]
0
0
Belo Horizonte
Query!
Country [67]
0
0
Brazil
Query!
State/province [67]
0
0
Botucatu -
Query!
Country [68]
0
0
Brazil
Query!
State/province [68]
0
0
Campinas
Query!
Country [69]
0
0
Brazil
Query!
State/province [69]
0
0
Cerqueira César - São Paulo
Query!
Country [70]
0
0
Brazil
Query!
State/province [70]
0
0
Curitiba
Query!
Country [71]
0
0
Brazil
Query!
State/province [71]
0
0
Goiania
Query!
Country [72]
0
0
Brazil
Query!
State/province [72]
0
0
Marília
Query!
Country [73]
0
0
Brazil
Query!
State/province [73]
0
0
Pelotas
Query!
Country [74]
0
0
Brazil
Query!
State/province [74]
0
0
Porto Alegre - Rs
Query!
Country [75]
0
0
Brazil
Query!
State/province [75]
0
0
Porto Alegre
Query!
Country [76]
0
0
Brazil
Query!
State/province [76]
0
0
Ribeirao Preto
Query!
Country [77]
0
0
Brazil
Query!
State/province [77]
0
0
Rio de Janeiro - Rj
Query!
Country [78]
0
0
Brazil
Query!
State/province [78]
0
0
Rio de Janeiro
Query!
Country [79]
0
0
Brazil
Query!
State/province [79]
0
0
Salvador
Query!
Country [80]
0
0
Brazil
Query!
State/province [80]
0
0
Santa Catalina
Query!
Country [81]
0
0
Brazil
Query!
State/province [81]
0
0
Sao Jose do Rio Preto
Query!
Country [82]
0
0
Brazil
Query!
State/province [82]
0
0
Sao Paulo
Query!
Country [83]
0
0
Brazil
Query!
State/province [83]
0
0
São Paulo
Query!
Country [84]
0
0
Brazil
Query!
State/province [84]
0
0
Vila Clementino, São Paulo
Query!
Country [85]
0
0
Canada
Query!
State/province [85]
0
0
Alberta
Query!
Country [86]
0
0
Canada
Query!
State/province [86]
0
0
British Columbia
Query!
Country [87]
0
0
Canada
Query!
State/province [87]
0
0
Manitoba
Query!
Country [88]
0
0
Canada
Query!
State/province [88]
0
0
Newfoundland and Labrador
Query!
Country [89]
0
0
Canada
Query!
State/province [89]
0
0
Nova Scotia
Query!
Country [90]
0
0
Canada
Query!
State/province [90]
0
0
Ontario
Query!
Country [91]
0
0
Canada
Query!
State/province [91]
0
0
Quebec
Query!
Country [92]
0
0
Canada
Query!
State/province [92]
0
0
Saskatchewan
Query!
Country [93]
0
0
China
Query!
State/province [93]
0
0
Beijing
Query!
Country [94]
0
0
China
Query!
State/province [94]
0
0
Changsha
Query!
Country [95]
0
0
China
Query!
State/province [95]
0
0
Chengdu
Query!
Country [96]
0
0
China
Query!
State/province [96]
0
0
Guangzhou
Query!
Country [97]
0
0
China
Query!
State/province [97]
0
0
Harbin
Query!
Country [98]
0
0
China
Query!
State/province [98]
0
0
HeBei Province
Query!
Country [99]
0
0
China
Query!
State/province [99]
0
0
Henan Province
Query!
Country [100]
0
0
China
Query!
State/province [100]
0
0
Hubei Province
Query!
Country [101]
0
0
China
Query!
State/province [101]
0
0
Nanjing
Query!
Country [102]
0
0
China
Query!
State/province [102]
0
0
QingDao
Query!
Country [103]
0
0
China
Query!
State/province [103]
0
0
ShanDong Province
Query!
Country [104]
0
0
China
Query!
State/province [104]
0
0
Shanghai
Query!
Country [105]
0
0
China
Query!
State/province [105]
0
0
Shen Yang
Query!
Country [106]
0
0
China
Query!
State/province [106]
0
0
Shijiazhuang
Query!
Country [107]
0
0
China
Query!
State/province [107]
0
0
Tianjin
Query!
Country [108]
0
0
China
Query!
State/province [108]
0
0
Weizikeng
Query!
Country [109]
0
0
China
Query!
State/province [109]
0
0
Wuhan
Query!
Country [110]
0
0
China
Query!
State/province [110]
0
0
Zhenzhou
Query!
Country [111]
0
0
Czech Republic
Query!
State/province [111]
0
0
Brno
Query!
Country [112]
0
0
Czech Republic
Query!
State/province [112]
0
0
Havirov
Query!
Country [113]
0
0
Czech Republic
Query!
State/province [113]
0
0
Kladno
Query!
Country [114]
0
0
Czech Republic
Query!
State/province [114]
0
0
Mlada Boleslav
Query!
Country [115]
0
0
Czech Republic
Query!
State/province [115]
0
0
Plzen
Query!
Country [116]
0
0
Czech Republic
Query!
State/province [116]
0
0
Prague 5
Query!
Country [117]
0
0
Czech Republic
Query!
State/province [117]
0
0
Prague
Query!
Country [118]
0
0
Czech Republic
Query!
State/province [118]
0
0
Praha 2
Query!
Country [119]
0
0
Czech Republic
Query!
State/province [119]
0
0
Pribram 1
Query!
Country [120]
0
0
Czech Republic
Query!
State/province [120]
0
0
Usti nad Orlici
Query!
Country [121]
0
0
Denmark
Query!
State/province [121]
0
0
Aalborg
Query!
Country [122]
0
0
Denmark
Query!
State/province [122]
0
0
Aarhus C
Query!
Country [123]
0
0
Denmark
Query!
State/province [123]
0
0
Frederiksberg C
Query!
Country [124]
0
0
Denmark
Query!
State/province [124]
0
0
Frederiksberg
Query!
Country [125]
0
0
Denmark
Query!
State/province [125]
0
0
Helsingoer
Query!
Country [126]
0
0
Denmark
Query!
State/province [126]
0
0
Hilleroed
Query!
Country [127]
0
0
Denmark
Query!
State/province [127]
0
0
Holbaek
Query!
Country [128]
0
0
Denmark
Query!
State/province [128]
0
0
Hvidovre
Query!
Country [129]
0
0
Denmark
Query!
State/province [129]
0
0
Kjellerup
Query!
Country [130]
0
0
Denmark
Query!
State/province [130]
0
0
Randers
Query!
Country [131]
0
0
Denmark
Query!
State/province [131]
0
0
Slagelse
Query!
Country [132]
0
0
Denmark
Query!
State/province [132]
0
0
Svendborg
Query!
Country [133]
0
0
Finland
Query!
State/province [133]
0
0
Helsinki
Query!
Country [134]
0
0
Finland
Query!
State/province [134]
0
0
Hämeenlinna
Query!
Country [135]
0
0
Finland
Query!
State/province [135]
0
0
Jyväskylä
Query!
Country [136]
0
0
Finland
Query!
State/province [136]
0
0
Kuopio
Query!
Country [137]
0
0
Finland
Query!
State/province [137]
0
0
Kuusankoski
Query!
Country [138]
0
0
Finland
Query!
State/province [138]
0
0
Liperi
Query!
Country [139]
0
0
Finland
Query!
State/province [139]
0
0
Oulun kaupunki
Query!
Country [140]
0
0
Finland
Query!
State/province [140]
0
0
Turku
Query!
Country [141]
0
0
Finland
Query!
State/province [141]
0
0
Vantaa
Query!
Country [142]
0
0
France
Query!
State/province [142]
0
0
Albens
Query!
Country [143]
0
0
France
Query!
State/province [143]
0
0
Beziers
Query!
Country [144]
0
0
France
Query!
State/province [144]
0
0
Bourges
Query!
Country [145]
0
0
France
Query!
State/province [145]
0
0
Broglie
Query!
Country [146]
0
0
France
Query!
State/province [146]
0
0
Castelnaudary
Query!
Country [147]
0
0
France
Query!
State/province [147]
0
0
Gemenos
Query!
Country [148]
0
0
France
Query!
State/province [148]
0
0
Husseren Wesserlin
Query!
Country [149]
0
0
France
Query!
State/province [149]
0
0
Hyeres
Query!
Country [150]
0
0
France
Query!
State/province [150]
0
0
L'Aigle
Query!
Country [151]
0
0
France
Query!
State/province [151]
0
0
La Rochelle
Query!
Country [152]
0
0
France
Query!
State/province [152]
0
0
Le Pradet
Query!
Country [153]
0
0
France
Query!
State/province [153]
0
0
Murs Erigne
Query!
Country [154]
0
0
France
Query!
State/province [154]
0
0
Nantes
Query!
Country [155]
0
0
France
Query!
State/province [155]
0
0
Niort
Query!
Country [156]
0
0
France
Query!
State/province [156]
0
0
Ortez
Query!
Country [157]
0
0
France
Query!
State/province [157]
0
0
Paris
Query!
Country [158]
0
0
France
Query!
State/province [158]
0
0
Rennes
Query!
Country [159]
0
0
France
Query!
State/province [159]
0
0
Rosiers d'Egletons
Query!
Country [160]
0
0
France
Query!
State/province [160]
0
0
Saint Julien des Landes
Query!
Country [161]
0
0
France
Query!
State/province [161]
0
0
Saint Martin dHyeres
Query!
Country [162]
0
0
France
Query!
State/province [162]
0
0
Saint Pierre de Chandieu
Query!
Country [163]
0
0
France
Query!
State/province [163]
0
0
Saint Romain sur Cher
Query!
Country [164]
0
0
France
Query!
State/province [164]
0
0
Strasbourg
Query!
Country [165]
0
0
France
Query!
State/province [165]
0
0
Tours
Query!
Country [166]
0
0
Germany
Query!
State/province [166]
0
0
Bad Lausick
Query!
Country [167]
0
0
Germany
Query!
State/province [167]
0
0
Bad Lauterberg
Query!
Country [168]
0
0
Germany
Query!
State/province [168]
0
0
Bad Mergentheim
Query!
Country [169]
0
0
Germany
Query!
State/province [169]
0
0
Berlin
Query!
Country [170]
0
0
Germany
Query!
State/province [170]
0
0
Bielefeld
Query!
Country [171]
0
0
Germany
Query!
State/province [171]
0
0
Dessau
Query!
Country [172]
0
0
Germany
Query!
State/province [172]
0
0
Dortmund
Query!
Country [173]
0
0
Germany
Query!
State/province [173]
0
0
Dresden
Query!
Country [174]
0
0
Germany
Query!
State/province [174]
0
0
Eberswalde
Query!
Country [175]
0
0
Germany
Query!
State/province [175]
0
0
Erlangen
Query!
Country [176]
0
0
Germany
Query!
State/province [176]
0
0
Essen
Query!
Country [177]
0
0
Germany
Query!
State/province [177]
0
0
Haag
Query!
Country [178]
0
0
Germany
Query!
State/province [178]
0
0
Hamburg
Query!
Country [179]
0
0
Germany
Query!
State/province [179]
0
0
Heidelberg
Query!
Country [180]
0
0
Germany
Query!
State/province [180]
0
0
Homburg/Saar
Query!
Country [181]
0
0
Germany
Query!
State/province [181]
0
0
Karlsburg
Query!
Country [182]
0
0
Germany
Query!
State/province [182]
0
0
Kelkheim
Query!
Country [183]
0
0
Germany
Query!
State/province [183]
0
0
Köln
Query!
Country [184]
0
0
Germany
Query!
State/province [184]
0
0
Künzing
Query!
Country [185]
0
0
Germany
Query!
State/province [185]
0
0
Lübeck
Query!
Country [186]
0
0
Germany
Query!
State/province [186]
0
0
Mainz
Query!
Country [187]
0
0
Germany
Query!
State/province [187]
0
0
Melsungen
Query!
Country [188]
0
0
Germany
Query!
State/province [188]
0
0
München
Query!
Country [189]
0
0
Germany
Query!
State/province [189]
0
0
Offenbach am Main
Query!
Country [190]
0
0
Germany
Query!
State/province [190]
0
0
Riesa
Query!
Country [191]
0
0
Germany
Query!
State/province [191]
0
0
Rostock
Query!
Country [192]
0
0
Germany
Query!
State/province [192]
0
0
Sindelfingen
Query!
Country [193]
0
0
Germany
Query!
State/province [193]
0
0
Starnberg
Query!
Country [194]
0
0
Germany
Query!
State/province [194]
0
0
Stuttgart
Query!
Country [195]
0
0
Germany
Query!
State/province [195]
0
0
Timmendorfer Strand
Query!
Country [196]
0
0
Germany
Query!
State/province [196]
0
0
Wiesbaden
Query!
Country [197]
0
0
Germany
Query!
State/province [197]
0
0
Witten
Query!
Country [198]
0
0
Greece
Query!
State/province [198]
0
0
Athens
Query!
Country [199]
0
0
Greece
Query!
State/province [199]
0
0
Elefsina
Query!
Country [200]
0
0
Greece
Query!
State/province [200]
0
0
Goudi/ Athens
Query!
Country [201]
0
0
Greece
Query!
State/province [201]
0
0
Ioannina
Query!
Country [202]
0
0
Greece
Query!
State/province [202]
0
0
Kavala,greece
Query!
Country [203]
0
0
Greece
Query!
State/province [203]
0
0
Korinthos
Query!
Country [204]
0
0
Greece
Query!
State/province [204]
0
0
Melissia, Athens
Query!
Country [205]
0
0
Greece
Query!
State/province [205]
0
0
Thessaloniki
Query!
Country [206]
0
0
Greece
Query!
State/province [206]
0
0
Veria
Query!
Country [207]
0
0
Hong Kong
Query!
State/province [207]
0
0
Hong Kong
Query!
Country [208]
0
0
Hungary
Query!
State/province [208]
0
0
Budapest
Query!
Country [209]
0
0
Hungary
Query!
State/province [209]
0
0
Debrecen
Query!
Country [210]
0
0
Hungary
Query!
State/province [210]
0
0
Kecskemet
Query!
Country [211]
0
0
Hungary
Query!
State/province [211]
0
0
Nyiregyhaza
Query!
Country [212]
0
0
Hungary
Query!
State/province [212]
0
0
Pecs
Query!
Country [213]
0
0
Hungary
Query!
State/province [213]
0
0
Siofok
Query!
Country [214]
0
0
Hungary
Query!
State/province [214]
0
0
Szeged
Query!
Country [215]
0
0
Hungary
Query!
State/province [215]
0
0
Szekesfehervar
Query!
Country [216]
0
0
Hungary
Query!
State/province [216]
0
0
Tatabanya
Query!
Country [217]
0
0
Hungary
Query!
State/province [217]
0
0
Veszprem
Query!
Country [218]
0
0
Ireland
Query!
State/province [218]
0
0
Dublin 24
Query!
Country [219]
0
0
Ireland
Query!
State/province [219]
0
0
Dublin 8
Query!
Country [220]
0
0
Ireland
Query!
State/province [220]
0
0
Dublin 9
Query!
Country [221]
0
0
Ireland
Query!
State/province [221]
0
0
Mallow
Query!
Country [222]
0
0
Italy
Query!
State/province [222]
0
0
Ascoli Piceno
Query!
Country [223]
0
0
Italy
Query!
State/province [223]
0
0
Bentivoglio (BO)
Query!
Country [224]
0
0
Italy
Query!
State/province [224]
0
0
Bologna
Query!
Country [225]
0
0
Italy
Query!
State/province [225]
0
0
Brescia
Query!
Country [226]
0
0
Italy
Query!
State/province [226]
0
0
Casarano (LE)
Query!
Country [227]
0
0
Italy
Query!
State/province [227]
0
0
Caserta
Query!
Country [228]
0
0
Italy
Query!
State/province [228]
0
0
Città della Pieve (PG)
Query!
Country [229]
0
0
Italy
Query!
State/province [229]
0
0
Ferrara
Query!
Country [230]
0
0
Italy
Query!
State/province [230]
0
0
Monfalcone (go)
Query!
Country [231]
0
0
Italy
Query!
State/province [231]
0
0
Napoli
Query!
Country [232]
0
0
Italy
Query!
State/province [232]
0
0
Palermo
Query!
Country [233]
0
0
Italy
Query!
State/province [233]
0
0
Pavia
Query!
Country [234]
0
0
Italy
Query!
State/province [234]
0
0
Perugia
Query!
Country [235]
0
0
Italy
Query!
State/province [235]
0
0
Pozzilli (IS)
Query!
Country [236]
0
0
Italy
Query!
State/province [236]
0
0
Roma
Query!
Country [237]
0
0
Italy
Query!
State/province [237]
0
0
S. Pietro Vernotico (BR)
Query!
Country [238]
0
0
Italy
Query!
State/province [238]
0
0
Sassari
Query!
Country [239]
0
0
Italy
Query!
State/province [239]
0
0
Torino
Query!
Country [240]
0
0
Italy
Query!
State/province [240]
0
0
Varese
Query!
Country [241]
0
0
Italy
Query!
State/province [241]
0
0
Venezia
Query!
Country [242]
0
0
Italy
Query!
State/province [242]
0
0
Viterbo
Query!
Country [243]
0
0
Korea, Republic of
Query!
State/province [243]
0
0
Incheon
Query!
Country [244]
0
0
Korea, Republic of
Query!
State/province [244]
0
0
Kwang-ju
Query!
Country [245]
0
0
Korea, Republic of
Query!
State/province [245]
0
0
Pusan
Query!
Country [246]
0
0
Korea, Republic of
Query!
State/province [246]
0
0
Seoul
Query!
Country [247]
0
0
Korea, Republic of
Query!
State/province [247]
0
0
Taegu
Query!
Country [248]
0
0
Malaysia
Query!
State/province [248]
0
0
Johor Baharu
Query!
Country [249]
0
0
Malaysia
Query!
State/province [249]
0
0
Kelantan Darul Naim
Query!
Country [250]
0
0
Malaysia
Query!
State/province [250]
0
0
Kelantan
Query!
Country [251]
0
0
Malaysia
Query!
State/province [251]
0
0
Kuala Lumpur
Query!
Country [252]
0
0
Malaysia
Query!
State/province [252]
0
0
Penang
Query!
Country [253]
0
0
Malaysia
Query!
State/province [253]
0
0
Putrajaya
Query!
Country [254]
0
0
Malaysia
Query!
State/province [254]
0
0
Selangor
Query!
Country [255]
0
0
Mexico
Query!
State/province [255]
0
0
Guadalajara
Query!
Country [256]
0
0
Mexico
Query!
State/province [256]
0
0
Mexico
Query!
Country [257]
0
0
Mexico
Query!
State/province [257]
0
0
Monterrey
Query!
Country [258]
0
0
Mexico
Query!
State/province [258]
0
0
Zapopan
Query!
Country [259]
0
0
Netherlands
Query!
State/province [259]
0
0
Amsterdam
Query!
Country [260]
0
0
Netherlands
Query!
State/province [260]
0
0
Beverwijk
Query!
Country [261]
0
0
Netherlands
Query!
State/province [261]
0
0
Den Bosch
Query!
Country [262]
0
0
Netherlands
Query!
State/province [262]
0
0
Den Haag
Query!
Country [263]
0
0
Netherlands
Query!
State/province [263]
0
0
Doetinchem
Query!
Country [264]
0
0
Netherlands
Query!
State/province [264]
0
0
Drachten
Query!
Country [265]
0
0
Netherlands
Query!
State/province [265]
0
0
Eindhoven
Query!
Country [266]
0
0
Netherlands
Query!
State/province [266]
0
0
Ermelo
Query!
Country [267]
0
0
Netherlands
Query!
State/province [267]
0
0
Ewijk
Query!
Country [268]
0
0
Netherlands
Query!
State/province [268]
0
0
Hengelo
Query!
Country [269]
0
0
Netherlands
Query!
State/province [269]
0
0
Hoorn
Query!
Country [270]
0
0
Netherlands
Query!
State/province [270]
0
0
Huizen
Query!
Country [271]
0
0
Netherlands
Query!
State/province [271]
0
0
Lichtenvoorde
Query!
Country [272]
0
0
Netherlands
Query!
State/province [272]
0
0
Losser
Query!
Country [273]
0
0
Netherlands
Query!
State/province [273]
0
0
Nieuwegein
Query!
Country [274]
0
0
Netherlands
Query!
State/province [274]
0
0
Rijswijk
Query!
Country [275]
0
0
Netherlands
Query!
State/province [275]
0
0
Roelofarendsveen
Query!
Country [276]
0
0
Netherlands
Query!
State/province [276]
0
0
Rotterdam
Query!
Country [277]
0
0
Netherlands
Query!
State/province [277]
0
0
Spijkenisse
Query!
Country [278]
0
0
Netherlands
Query!
State/province [278]
0
0
Stadskanaal
Query!
Country [279]
0
0
Netherlands
Query!
State/province [279]
0
0
Tilburg
Query!
Country [280]
0
0
Netherlands
Query!
State/province [280]
0
0
Utrecht
Query!
Country [281]
0
0
Netherlands
Query!
State/province [281]
0
0
Velp
Query!
Country [282]
0
0
New Zealand
Query!
State/province [282]
0
0
Auckland 3
Query!
Country [283]
0
0
New Zealand
Query!
State/province [283]
0
0
Auckland
Query!
Country [284]
0
0
New Zealand
Query!
State/province [284]
0
0
Christchurch
Query!
Country [285]
0
0
New Zealand
Query!
State/province [285]
0
0
Hamiton
Query!
Country [286]
0
0
New Zealand
Query!
State/province [286]
0
0
Hasting
Query!
Country [287]
0
0
New Zealand
Query!
State/province [287]
0
0
Otahuhu Auckland
Query!
Country [288]
0
0
New Zealand
Query!
State/province [288]
0
0
Takapuna Auckland
Query!
Country [289]
0
0
New Zealand
Query!
State/province [289]
0
0
Tauranga
Query!
Country [290]
0
0
Norway
Query!
State/province [290]
0
0
Fevik
Query!
Country [291]
0
0
Norway
Query!
State/province [291]
0
0
Nesttun
Query!
Country [292]
0
0
Norway
Query!
State/province [292]
0
0
Stavanger
Query!
Country [293]
0
0
Norway
Query!
State/province [293]
0
0
Tvedestrand
Query!
Country [294]
0
0
Norway
Query!
State/province [294]
0
0
Tønsberg
Query!
Country [295]
0
0
Philippines
Query!
State/province [295]
0
0
Cavite
Query!
Country [296]
0
0
Philippines
Query!
State/province [296]
0
0
Manila
Query!
Country [297]
0
0
Philippines
Query!
State/province [297]
0
0
Pasig City
Query!
Country [298]
0
0
Philippines
Query!
State/province [298]
0
0
Quezon City
Query!
Country [299]
0
0
Poland
Query!
State/province [299]
0
0
Bydgoszcz
Query!
Country [300]
0
0
Poland
Query!
State/province [300]
0
0
Czestochowa
Query!
Country [301]
0
0
Poland
Query!
State/province [301]
0
0
Gdynia Redlowo
Query!
Country [302]
0
0
Poland
Query!
State/province [302]
0
0
Gdynia
Query!
Country [303]
0
0
Poland
Query!
State/province [303]
0
0
Grojec
Query!
Country [304]
0
0
Poland
Query!
State/province [304]
0
0
Grudziadz
Query!
Country [305]
0
0
Poland
Query!
State/province [305]
0
0
Inowroclaw
Query!
Country [306]
0
0
Poland
Query!
State/province [306]
0
0
Jaroslawiec
Query!
Country [307]
0
0
Poland
Query!
State/province [307]
0
0
Katowice
Query!
Country [308]
0
0
Poland
Query!
State/province [308]
0
0
Kielce
Query!
Country [309]
0
0
Poland
Query!
State/province [309]
0
0
Lodz
Query!
Country [310]
0
0
Poland
Query!
State/province [310]
0
0
Lubartow
Query!
Country [311]
0
0
Poland
Query!
State/province [311]
0
0
Lubin
Query!
Country [312]
0
0
Poland
Query!
State/province [312]
0
0
Nowy Sacz
Query!
Country [313]
0
0
Poland
Query!
State/province [313]
0
0
Piotrkow Trybunalski
Query!
Country [314]
0
0
Poland
Query!
State/province [314]
0
0
Poznan
Query!
Country [315]
0
0
Poland
Query!
State/province [315]
0
0
Ruda Slaska
Query!
Country [316]
0
0
Poland
Query!
State/province [316]
0
0
Skierniewice
Query!
Country [317]
0
0
Poland
Query!
State/province [317]
0
0
Tarnow
Query!
Country [318]
0
0
Poland
Query!
State/province [318]
0
0
Tomaszow Mazowiecki
Query!
Country [319]
0
0
Poland
Query!
State/province [319]
0
0
Torun
Query!
Country [320]
0
0
Poland
Query!
State/province [320]
0
0
Warsaw
Query!
Country [321]
0
0
Poland
Query!
State/province [321]
0
0
Wegrow
Query!
Country [322]
0
0
Portugal
Query!
State/province [322]
0
0
Almada
Query!
Country [323]
0
0
Portugal
Query!
State/province [323]
0
0
Amadora
Query!
Country [324]
0
0
Portugal
Query!
State/province [324]
0
0
Carnaxide
Query!
Country [325]
0
0
Portugal
Query!
State/province [325]
0
0
Coimbra
Query!
Country [326]
0
0
Portugal
Query!
State/province [326]
0
0
Faro
Query!
Country [327]
0
0
Portugal
Query!
State/province [327]
0
0
Lisboa
Query!
Country [328]
0
0
Portugal
Query!
State/province [328]
0
0
Matosinhos
Query!
Country [329]
0
0
Portugal
Query!
State/province [329]
0
0
Porto
Query!
Country [330]
0
0
Portugal
Query!
State/province [330]
0
0
Vila Nova de Gaia
Query!
Country [331]
0
0
Puerto Rico
Query!
State/province [331]
0
0
Caguas
Query!
Country [332]
0
0
Puerto Rico
Query!
State/province [332]
0
0
Las Lomas
Query!
Country [333]
0
0
Puerto Rico
Query!
State/province [333]
0
0
Manati
Query!
Country [334]
0
0
Puerto Rico
Query!
State/province [334]
0
0
Orocovis
Query!
Country [335]
0
0
Puerto Rico
Query!
State/province [335]
0
0
Rio Piedras
Query!
Country [336]
0
0
Russian Federation
Query!
State/province [336]
0
0
Moscow
Query!
Country [337]
0
0
Russian Federation
Query!
State/province [337]
0
0
St. Petersburg
Query!
Country [338]
0
0
Singapore
Query!
State/province [338]
0
0
Kuala Lumpur
Query!
Country [339]
0
0
Singapore
Query!
State/province [339]
0
0
Singapore
Query!
Country [340]
0
0
Slovakia
Query!
State/province [340]
0
0
Bratislava
Query!
Country [341]
0
0
Slovakia
Query!
State/province [341]
0
0
Kosice
Query!
Country [342]
0
0
Slovakia
Query!
State/province [342]
0
0
Nitra
Query!
Country [343]
0
0
Slovakia
Query!
State/province [343]
0
0
Rimavska Sobota
Query!
Country [344]
0
0
South Africa
Query!
State/province [344]
0
0
Bellville
Query!
Country [345]
0
0
South Africa
Query!
State/province [345]
0
0
Bloemfontein
Query!
Country [346]
0
0
South Africa
Query!
State/province [346]
0
0
Cape Town
Query!
Country [347]
0
0
South Africa
Query!
State/province [347]
0
0
Congella
Query!
Country [348]
0
0
South Africa
Query!
State/province [348]
0
0
Durban
Query!
Country [349]
0
0
South Africa
Query!
State/province [349]
0
0
Fiachrdtpark, Bloemfontein
Query!
Country [350]
0
0
South Africa
Query!
State/province [350]
0
0
George East
Query!
Country [351]
0
0
South Africa
Query!
State/province [351]
0
0
Park Town West
Query!
Country [352]
0
0
South Africa
Query!
State/province [352]
0
0
Port Elizabeth
Query!
Country [353]
0
0
South Africa
Query!
State/province [353]
0
0
Soweto
Query!
Country [354]
0
0
South Africa
Query!
State/province [354]
0
0
Sunninghill
Query!
Country [355]
0
0
South Africa
Query!
State/province [355]
0
0
Vanderbijlpark
Query!
Country [356]
0
0
Spain
Query!
State/province [356]
0
0
Alcorcón (Madrid)
Query!
Country [357]
0
0
Spain
Query!
State/province [357]
0
0
Alicante
Query!
Country [358]
0
0
Spain
Query!
State/province [358]
0
0
Barcelona
Query!
Country [359]
0
0
Spain
Query!
State/province [359]
0
0
Burjasot (Valencia)
Query!
Country [360]
0
0
Spain
Query!
State/province [360]
0
0
Granada
Query!
Country [361]
0
0
Spain
Query!
State/province [361]
0
0
Madrid
Query!
Country [362]
0
0
Spain
Query!
State/province [362]
0
0
Murcia
Query!
Country [363]
0
0
Spain
Query!
State/province [363]
0
0
Málaga
Query!
Country [364]
0
0
Spain
Query!
State/province [364]
0
0
Santiago de Compostela
Query!
Country [365]
0
0
Spain
Query!
State/province [365]
0
0
Sevilla
Query!
Country [366]
0
0
Spain
Query!
State/province [366]
0
0
Valencia
Query!
Country [367]
0
0
Sweden
Query!
State/province [367]
0
0
Göteborg
Query!
Country [368]
0
0
Sweden
Query!
State/province [368]
0
0
Helsingborg
Query!
Country [369]
0
0
Sweden
Query!
State/province [369]
0
0
Järfälla
Query!
Country [370]
0
0
Sweden
Query!
State/province [370]
0
0
Malmoe
Query!
Country [371]
0
0
Sweden
Query!
State/province [371]
0
0
Malmö
Query!
Country [372]
0
0
Sweden
Query!
State/province [372]
0
0
Sjuntorp
Query!
Country [373]
0
0
Sweden
Query!
State/province [373]
0
0
Trollhättan
Query!
Country [374]
0
0
Sweden
Query!
State/province [374]
0
0
Vännäs
Query!
Country [375]
0
0
Switzerland
Query!
State/province [375]
0
0
Basel
Query!
Country [376]
0
0
Switzerland
Query!
State/province [376]
0
0
Bellinzona
Query!
Country [377]
0
0
Switzerland
Query!
State/province [377]
0
0
Bern
Query!
Country [378]
0
0
Switzerland
Query!
State/province [378]
0
0
Biel/Bienne
Query!
Country [379]
0
0
Switzerland
Query!
State/province [379]
0
0
Chur
Query!
Country [380]
0
0
Switzerland
Query!
State/province [380]
0
0
Kreuzlingen
Query!
Country [381]
0
0
Switzerland
Query!
State/province [381]
0
0
Lausanne
Query!
Country [382]
0
0
Switzerland
Query!
State/province [382]
0
0
Lugano
Query!
Country [383]
0
0
Switzerland
Query!
State/province [383]
0
0
St. Gallen
Query!
Country [384]
0
0
Switzerland
Query!
State/province [384]
0
0
Zürich
Query!
Country [385]
0
0
Taiwan
Query!
State/province [385]
0
0
Changhua
Query!
Country [386]
0
0
Taiwan
Query!
State/province [386]
0
0
Chia-Yi
Query!
Country [387]
0
0
Taiwan
Query!
State/province [387]
0
0
Hualien
Query!
Country [388]
0
0
Taiwan
Query!
State/province [388]
0
0
Kaohsiung
Query!
Country [389]
0
0
Taiwan
Query!
State/province [389]
0
0
Tainan
Query!
Country [390]
0
0
Taiwan
Query!
State/province [390]
0
0
Taipei
Query!
Country [391]
0
0
Thailand
Query!
State/province [391]
0
0
Bangkok
Query!
Country [392]
0
0
Thailand
Query!
State/province [392]
0
0
Khon Kaen
Query!
Country [393]
0
0
Thailand
Query!
State/province [393]
0
0
Nonthaburi
Query!
Country [394]
0
0
Turkey
Query!
State/province [394]
0
0
Adana
Query!
Country [395]
0
0
Turkey
Query!
State/province [395]
0
0
Ankara
Query!
Country [396]
0
0
Turkey
Query!
State/province [396]
0
0
Istanbul
Query!
Country [397]
0
0
Turkey
Query!
State/province [397]
0
0
Izmir
Query!
Country [398]
0
0
Turkey
Query!
State/province [398]
0
0
Kayseri
Query!
Country [399]
0
0
Ukraine
Query!
State/province [399]
0
0
Dnyepropetrovsk
Query!
Country [400]
0
0
Ukraine
Query!
State/province [400]
0
0
Kharkov
Query!
Country [401]
0
0
Ukraine
Query!
State/province [401]
0
0
Kiev
Query!
Country [402]
0
0
United Arab Emirates
Query!
State/province [402]
0
0
Abu Dhabi
Query!
Country [403]
0
0
United Arab Emirates
Query!
State/province [403]
0
0
Dubai
Query!
Country [404]
0
0
United Arab Emirates
Query!
State/province [404]
0
0
Sharjah
Query!
Country [405]
0
0
United Kingdom
Query!
State/province [405]
0
0
Aberdeen
Query!
Country [406]
0
0
United Kingdom
Query!
State/province [406]
0
0
Bathampton
Query!
Country [407]
0
0
United Kingdom
Query!
State/province [407]
0
0
Belfast
Query!
Country [408]
0
0
United Kingdom
Query!
State/province [408]
0
0
Birmingham
Query!
Country [409]
0
0
United Kingdom
Query!
State/province [409]
0
0
Brighton
Query!
Country [410]
0
0
United Kingdom
Query!
State/province [410]
0
0
Cardiff
Query!
Country [411]
0
0
United Kingdom
Query!
State/province [411]
0
0
Chichester
Query!
Country [412]
0
0
United Kingdom
Query!
State/province [412]
0
0
Derby
Query!
Country [413]
0
0
United Kingdom
Query!
State/province [413]
0
0
Gateshead
Query!
Country [414]
0
0
United Kingdom
Query!
State/province [414]
0
0
Glasgow
Query!
Country [415]
0
0
United Kingdom
Query!
State/province [415]
0
0
Kirkcaldy, Fife
Query!
Country [416]
0
0
United Kingdom
Query!
State/province [416]
0
0
Leeds
Query!
Country [417]
0
0
United Kingdom
Query!
State/province [417]
0
0
Leicester
Query!
Country [418]
0
0
United Kingdom
Query!
State/province [418]
0
0
Lincoln
Query!
Country [419]
0
0
United Kingdom
Query!
State/province [419]
0
0
Liverpool
Query!
Country [420]
0
0
United Kingdom
Query!
State/province [420]
0
0
London
Query!
Country [421]
0
0
United Kingdom
Query!
State/province [421]
0
0
Manchester
Query!
Country [422]
0
0
United Kingdom
Query!
State/province [422]
0
0
Portadown, County Atrim
Query!
Country [423]
0
0
United Kingdom
Query!
State/province [423]
0
0
Rugby
Query!
Country [424]
0
0
United Kingdom
Query!
State/province [424]
0
0
Sheffield
Query!
Country [425]
0
0
United Kingdom
Query!
State/province [425]
0
0
Stirling
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint. Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00153101
Query!
Trial related presentations / publications
Bohm M, Schumacher H, Werner C, Teo KK, Lonn EM, Mahfoud F, Speer T, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Laufs U, Williams B, Yusuf S, Mann JFE. Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovasc Diabetol. 2022 Jan 20;21(1):12. doi: 10.1186/s12933-021-01429-w. Bohm M, Schumacher H, Teo KK, Lonn EM, Lauder L, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE, Mahfoud F. Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. J Hypertens. 2021 Aug 1;39(8):1602-1610. doi: 10.1097/HJH.0000000000002822. Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Emrich I, Mancia G, Redon J, Schmieder RE, Sliwa K, Lehrke M, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertens. 2021 Apr 1;39(4):766-774. doi: 10.1097/HJH.0000000000002697. Mancia G, Schumacher H, Bohm M, Mann JFE, Redon J, Facchetti R, Schmieder RE, Lonn EM, Teo KK, Yusuf S. Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. J Hypertens. 2020 Oct;38(10):2050-2058. doi: 10.1097/HJH.0000000000002567. Dehghan M, Mente A, Rangarajan S, Mohan V, Lear S, Swaminathan S, Wielgosz A, Seron P, Avezum A, Lopez-Jaramillo P, Turbide G, Chifamba J, AlHabib KF, Mohammadifard N, Szuba A, Khatib R, Altuntas Y, Liu X, Iqbal R, Rosengren A, Yusuf R, Smuts M, Yusufali A, Li N, Diaz R, Yusoff K, Kaur M, Soman B, Ismail N, Gupta R, Dans A, Sheridan P, Teo K, Anand SS, Yusuf S. Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. Am J Clin Nutr. 2020 Apr 1;111(4):795-803. doi: 10.1093/ajcn/nqz348. Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, Sliwa K, Weber MA, Williams B, Yusuf S. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. Eur Heart J. 2019 Jul 1;40(25):2032-2043. doi: 10.1093/eurheartj/ehz149. Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Ukena C, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S. Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. Eur Heart J. 2020 Jan 7;41(2):231-238. doi: 10.1093/eurheartj/ehy808. Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7. Epub 2017 Apr 5. Dunkler D, Kohl M, Teo KK, Heinze G, Dehghan M, Clase CM, Gao P, Yusuf S, Mann JF, Oberbauer R. Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv76-85. doi: 10.1093/ndt/gfv086. Bohm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, O'Donnell M, Yusuf S. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension. 2015 Mar;65(3):651-61. doi: 10.1161/HYPERTENSIONAHA.114.04568. Epub 2015 Jan 12. Verdecchia P, Reboldi G, Angeli F, Trimarco B, Mancia G, Pogue J, Gao P, Sleight P, Teo K, Yusuf S. Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. Hypertension. 2015 Jan;65(1):108-14. doi: 10.1161/HYPERTENSIONAHA.114.04310. Epub 2014 Oct 20. Lonn EM, Rambihar S, Gao P, Custodis FF, Sliwa K, Teo KK, Yusuf S, Bohm M. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol. 2014 Feb;103(2):149-59. doi: 10.1007/s00392-013-0644-4. Epub 2013 Dec 20. Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4. Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med. 2013 Oct 14;173(18):1682-92. doi: 10.1001/jamainternmed.2013.9051. Bohm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J. 2013 Aug;166(2):306-314.e7. doi: 10.1016/j.ahj.2013.04.016. Epub 2013 Jun 24. Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, Avezum A, Probstfield JL, Dans T, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial Investigators. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Circulation. 2012 Dec 4;126(23):2705-12. doi: 10.1161/CIRCULATIONAHA.112.103234. Barzilay JI, Gao P, Clase CM, Mente A, Mann JF, Sleight P, Yusuf S, Teo KK; OnTARGET/TRANSCEND Investigators. Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures. Clin J Am Soc Nephrol. 2013 Feb;8(2):233-40. doi: 10.2215/CJN.06640712. Epub 2012 Nov 26. Kappert K, Bohm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T; ONTARGET/TRANSCEND Investigators. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012 Aug 21;126(8):934-41. doi: 10.1161/CIRCULATIONAHA.111.086660. Epub 2012 Jul 24. Neumann I, Grassi B. [Critically appraised article]. Rev Med Chil. 2012 Jan;140(1):117-20. Epub 2012 Apr 12. Spanish. Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. J Hypertens. 2012 May;30(5):1004-14. doi: 10.1097/HJH.0b013e3283522a51. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Bohm M, Williams B, Yusoff K, Teo K, Yusuf S; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. doi: 10.1016/j.jacc.2011.09.040. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011 Oct 18;124(16):1727-36. doi: 10.1161/CIRCULATIONAHA.110.008870. Epub 2011 Sep 26. Barzilay JI, Gao P, Ryden L, Schumacher H, Probstfield J, Commerford P, Dans A, Ferreira R, Keltai M, Paolasso E, Yusuf S, Teo K; TRANSCEND Investigators. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care. 2011 Sep;34(9):1902-7. doi: 10.2337/dc11-0545. Epub 2011 Jul 25. Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF; ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011 Mar 15;123(10):1098-107. doi: 10.1161/CIRCULATIONAHA.110.964171. Epub 2011 Feb 28. Barzilay JI, Gao P, O'Donnell M, Mann JF, Anderson C, Fagard R, Probstfield J, Dagenais GR, Teo K, Yusuf S; ONTARGET and TRANSCEND Investigators. Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. Arch Intern Med. 2011 Jan 24;171(2):142-50. doi: 10.1001/archinternmed.2010.502. Dans AL, Teo K, Gao P, Chen JH, Jae-Hyung K, Yusoff K, Chaithiraphan S, Zhu J, Lisheng L, Yusuf S; Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial Investigators. In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. PLoS One. 2010 Dec 21;5(12):e13694. doi: 10.1371/journal.pone.0013694. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J, Paolasso E, Holwerda N, Chazova I, Binbrek A, Young J, Yusuf S; ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011 Jan;10(1):43-53. doi: 10.1016/S1474-4422(10)70250-7. Epub 2010 Oct 25. Bohm M, Baumhakel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15. Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009 Oct 6;120(14):1380-9. doi: 10.1161/CIRCULATIONAHA.109.865774. Epub 2009 Sep 21. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Bohm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009 Jul;27(7):1360-9. doi: 10.1097/HJH.0b013e32832d7370. Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Ryden L, Yu CM, Teo KK, Yusuf S; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009 Jul 7;151(1):1-10, W1-2. doi: 10.7326/0003-4819-151-1-200907070-00122. Epub 2009 May 18. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Erratum In: Lancet. 2008 Oct 18;372(9647):1384. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K; ONTARGET/TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007 Mar 20;115(11):1371-5. doi: 10.1161/CIRCULATIONAHA.106.661405. Epub 2007 Mar 5.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00153101
Download to PDF
Show all queries